Health Catalyst (HCAT)
NASDAQ:HCAT
Want to see HCAT full AI Analyst Report?
HCAT Stock Chart & Stats
$1.32
$0.34(4.94%)
At close: 4:00 PM EST
$1.32
$0.34(4.94%)
Day’s Range― - ―
52-Week Range$0.96 - $4.29
Previous CloseN/A
Volume315.36K
Average Volume (3M)628.93K
Market Cap
$98.28M
Enterprise Value$60.95M
Total Cash (Recent Filing)$108.82M
Total Debt (Recent Filing)$18.84M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Aug 12, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.72
Shares Outstanding73,894,020
10 Day Avg. Volume592,331
30 Day Avg. Volume628,929
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.54
P/FCF Ratio-704.86
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue0.20
Enterprise Value/Gross Profit0.44
Enterprise Value/Ebitda-0.65
Forecast
1Y Price Target
$2.11Price Target Upside59.63% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)0.04
Revenue Forecast (FY)$263.04M
Bulls Say, Bears Say
Bulls Say
Balance-sheet De-riskingThe planned Vitalware divestiture and term‑loan payoff materially reduces leverage and covenant/interest risk, improving liquidity and strategic optionality. Lower debt enhances the firm's ability to fund the technology shift, absorb migration noise, and extend runway without new dilutive financing.
Improved Cash GenerationReturn to positive operating and free cash flow signals that core operations now generate internal funding. Durable cash generation increases resilience during migration and restructuring, supports capex and product investment, and reduces reliance on external capital for near-term transformation.
Margin And Structural Cost ProgramA coherent, quantified cost program tied to headcount and operating simplification can sustainably boost adjusted margins if executed. Combined with a shift toward higher‑margin technology offerings and AI efficiency gains, Project NEXUS improves long‑term profitability potential and operating leverage.
Bears Say
Migration-driven Churn / At-risk ARRLarge migration and product transition create structural revenue visibility risk: multi‑year at‑risk ARR and notified downsells materially reduce near‑term revenue and complicate renewal timing. This diminishes predictability of recurring revenue and pressures growth even as tech mix improves.
Stagnant/declining Revenue And Deep LossesPersistently negative net margins and falling revenue show the firm has yet to convert product and cost initiatives into durable profitability. Wide accounting losses limit reinvestment capacity and equity value creation absent sustained revenue recovery and margin expansion over multiple quarters.
Low And Declining Services MarginsServices remain a low‑margin revenue source and are shrinking by design. As services compress, near‑term revenue base and cash flow from implementation work may decline, increasing dependence on technology sales to scale margins and creating execution risk during the migration to a software‑first model.
Health Catalyst News
HCAT FAQ
What was Health Catalyst’s price range in the past 12 months?
Health Catalyst lowest stock price was $0.95 and its highest was $4.29 in the past 12 months.
What is Health Catalyst’s market cap?
Health Catalyst’s market cap is $98.28M.
When is Health Catalyst’s upcoming earnings report date?
Health Catalyst’s upcoming earnings report date is Aug 12, 2026 which is in 68 days.
How were Health Catalyst’s earnings last quarter?
Health Catalyst released its earnings results on May 11, 2026. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of $0.011 by $0.009.
Is Health Catalyst overvalued?
According to Wall Street analysts Health Catalyst’s price is currently Undervalued.
Does Health Catalyst pay dividends?
Health Catalyst does not currently pay dividends.
What is Health Catalyst’s EPS estimate?
Health Catalyst’s EPS estimate is 0.03.
How many shares outstanding does Health Catalyst have?
Health Catalyst has 73,894,020 shares outstanding.
What happened to Health Catalyst’s price movement after its last earnings report?
Health Catalyst reported an EPS of $0.02 in its last earnings report, beating expectations of $0.011. Following the earnings report the stock price went up 7.246%.
Which hedge fund is a major shareholder of Health Catalyst?
Currently, no hedge funds are holding shares in HCAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Health Catalyst Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.11 (59.63% Upside)
$2.11 (59.63% Upside)
Blogger Sentiment
Bullish
HCAT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 793.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.50%
12-Months-Change
Fundamentals
Return on Equity
-99.78%
Trailing 12-Months
Asset Growth
-53.77%
Trailing 12-Months
Company Description
Health Catalyst
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.
HCAT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational and financial progress with meaningful near-term headwinds. Positives include a revenue beat, improved adjusted gross margin, a sizable adjusted EBITDA beat, strong cash generation, a detailed restructuring program (Project NEXUS) targeting ~$30M of annualized savings, early product and AI traction, and reinstated full-year guidance. Negatives center on migration-driven churn (~$30M at-risk ARR with an expected ~$20M 2026 impact), transitional duplicate hosting and data-loading costs weighing on margins, expected professional services margin decline, and near-term restructuring charges and execution risk. Overall, management laid out a coherent plan to address issues and improve long-term durability but acknowledged short-term revenue and margin pressure tied to migration and transformation.View all HCAT earnings summariesHCAT Stock 12 Month Forecast
Average Price Target
$2.11
▲(59.63% Upside)
Technical Analysis
HealthStream
―
OptimizeRx
―
Evolent Health
―
SOPHiA GENETICS
―
Definitive Healthcare Corp
―
Ownership Overview
7.86% Insiders
13.67% Mutual Funds
53.01% Other Institutional Investors
14.88% Public Companies and
Individual Investors